Carola Berking
Overview
Explore the profile of Carola Berking including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
306
Citations
7523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forschner A, Kahler K, Gschnell M, Langan E, Weishaupt C, Meiss F, et al.
Front Immunol
. 2025 Mar;
16:1509886.
PMID: 40066437
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life...
2.
Munoz Couselo E, Berking C, Baurain J, Martelli S, Arntz R, Savoia P
J Eur Acad Dermatol Venereol
. 2025 Mar;
PMID: 40055950
No abstract available.
3.
Placke J, Rajcsanyi L, Herbst R, Terheyden P, Utikal J, Pfohler C, et al.
Front Immunol
. 2025 Mar;
16:1536642.
PMID: 40028330
Background: Modern therapeutic strategies have significantly improved the prognosis of advanced melanoma patients. Predictive factors of therapy response include serum LDH; however, predictive markers for long-term survival are currently largely...
4.
Sauerer T, Bremm F, Beenen A, Heger L, Dudziak D, Bosch N, et al.
MedComm (2020)
. 2025 Feb;
6(3):e70111.
PMID: 39974665
No abstract available.
5.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
6.
Yalcin Mutlu M, Kleyer A, Kroenke G, Fagni F, Temiz S, Meder C, et al.
BMJ Open
. 2025 Jan;
15(1):e088486.
PMID: 39773803
Objectives: Although patients with immune-mediated inflammatory diseases (IMID) are thought to be more susceptible to viral infections, it is unclear whether their presentation differs between patients with IMID and healthy...
7.
Pfister F, Carnell L, Loffler L, Boosz P, Schaft N, Dorrie J, et al.
MedComm (2020)
. 2025 Jan;
6(1):e70039.
PMID: 39764559
Therapies against hematological malignancies using chimeric antigen receptors (CAR)-T cells have shown great potential; however, therapeutic success in solid tumors has been constrained due to limited tumor trafficking and infiltration,...
8.
Fakhouri S, Zhu H, Li Y, Ronicke M, Rius Rigau A, Dees C, et al.
Arthritis Rheumatol
. 2024 Dec;
PMID: 39722197
Objective: Little is known on the mechanisms necessary to maintain the physiologic adult human skin integrity. This study aims to quantitatively describe anatomic changes in systemic sclerosis (SSc)-skin compared with...
9.
Amaral T, Nanz L, Higuita L, Ascierto P, Berking C, Munoz Couselo E, et al.
Eur J Cancer
. 2024 Dec;
215:115160.
PMID: 39673834
Background: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting....
10.
Kott J, Zell T, Zimmermann N, Runger A, Smit D, Abeck F, et al.
Eur J Cancer
. 2024 Dec;
214():115159.
PMID: 39642845
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through...